DB:5TA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.

Share Price & News

How has Aimmune Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 5TA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.7%

5TA

5.3%

DE Biotechs

0.2%

DE Market


1 Year Return

43.4%

5TA

5.5%

DE Biotechs

6.6%

DE Market

Return vs Industry: 5TA exceeded the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: 5TA exceeded the German Market which returned 6.6% over the past year.


Shareholder returns

5TAIndustryMarket
7 Day0.7%5.3%0.2%
30 Day156.6%2.8%2.1%
90 Day71.6%7.8%5.6%
1 Year43.4%43.4%5.7%5.5%9.1%6.6%
3 Year46.7%46.7%20.5%19.3%6.8%-1.8%
5 Year29.9%29.9%49.5%47.1%38.9%20.1%

Price Volatility Vs. Market

How volatile is Aimmune Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aimmune Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 5TA (€29) is trading below our estimate of fair value (€115.13)

Significantly Below Fair Value: 5TA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 5TA is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: 5TA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 5TA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 5TA is overvalued based on its PB Ratio (12.5x) compared to the DE Biotechs industry average (5.7x).


Next Steps

Future Growth

How is Aimmune Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

70.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5TA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 5TA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 5TA's is expected to become profitable in the next 3 years.

Revenue vs Market: 5TA's revenue (68.7% per year) is forecast to grow faster than the German market (6% per year).

High Growth Revenue: 5TA's revenue (68.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 5TA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aimmune Therapeutics performed over the past 5 years?

-39.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 5TA is currently unprofitable.

Growing Profit Margin: 5TA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 5TA is unprofitable, and losses have increased over the past 5 years at a rate of 39% per year.

Accelerating Growth: Unable to compare 5TA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5TA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).


Return on Equity

High ROE: 5TA has a negative Return on Equity (-159.59%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aimmune Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 5TA's short term assets ($323.6M) exceed its short term liabilities ($43.0M).

Long Term Liabilities: 5TA's short term assets ($323.6M) exceed its long term liabilities ($142.4M).


Debt to Equity History and Analysis

Debt Level: 5TA's debt to equity ratio (73.1%) is considered high.

Reducing Debt: Insufficient data to determine if 5TA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 5TA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 5TA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Aimmune Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 5TA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 5TA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 5TA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5TA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5TA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Jayson Donald Dallas (52 yo)

2.25yrs

Tenure

US$4,744,109

Compensation

Dr. Jayson Donald Alexander Dallas, M.D. has been President, Chief Executive Officer and Director of Aimmune Therapeutics, Inc. since June 19, 2018. He served as the Chief Commercial Officer and Executive ...


CEO Compensation Analysis

Compensation vs Market: Jayson Donald's total compensation ($USD4.74M) is above average for companies of similar size in the German market ($USD1.56M).

Compensation vs Earnings: Jayson Donald's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jayson Donald Dallas
President2.25yrsUS$4.74m0.040%
$ 756.5k
Eric Bjerkholt
Chief Financial Officer3.42yrsUS$2.05m0.035%
$ 657.1k
Douglas Sheehy
General Counsel & Secretary4.42yrsUS$1.94m0.036%
$ 692.9k
Daniel Adelman
Chief Medical Officer4.25yrsUS$1.92m0.013%
$ 241.8k
Andrew Oxtoby
Chief Commercial Officer1.67yrsUS$2.98m0.011%
$ 203.2k
Narinderjeet Singh
Executive Vice President of Technical Operations0.17yrno datano data
DeDe Sheel
Vice President of Investor Relationsno datano datano data
Alicia Goodman
Senior Vice President of Human Resourcesno datano datano data
Becki Filice
Senior Vice President of Product & Portfolio Management2.67yrsno datano data
Samina Bari
Senior Vice President of Corporate Affairsno datano datano data
Steve Tilles
Senior Director of Medical Affairsno datano datano data

2.7yrs

Average Tenure

53yo

Average Age

Experienced Management: 5TA's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jayson Donald Dallas
President2.25yrsUS$4.74m0.040%
$ 756.5k
Kathryn Falberg
Independent Director5.33yrsUS$324.77k0.21%
$ 3.9m
Mark McDade
Independent Chairman of the Board5.33yrsUS$347.14k0.041%
$ 777.4k
Patrick Enright
Independent Director7.42yrsUS$316.64k0.11%
$ 2.0m
Mark Iwicki
Independent Director5.33yrsUS$309.52k0.060%
$ 1.1m
Stacey Seltzer
Independent Director5.67yrsUS$311.77k0.016%
$ 295.9k
A. Burks
Member of Scientific Advisory Board3.75yrsno datano data
Grégory Behar
Independent Director3.83yrsUS$297.64k0.015%
$ 295.1k
Brian Vickery
Member of Scientific Advisory Boardno datano datano data
Kirsten Beyer
Member of Scientific Advisory Board3.75yrsno datano data
Jonathan Hourihane
Member of Scientific Advisory Board3.75yrsno datano data
Stacie Jones
Member of Scientific Advisory Board3.75yrsno datano data

3.8yrs

Average Tenure

54yo

Average Age

Experienced Board: 5TA's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.


Top Shareholders

Company Information

Aimmune Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aimmune Therapeutics, Inc.
  • Ticker: 5TA
  • Exchange: DB
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.255b
  • Listing Market Cap: US$1.904b
  • Shares outstanding: 65.77m
  • Website: https://www.aimmune.com

Number of Employees


Location

  • Aimmune Therapeutics, Inc.
  • 8000 Marina Boulevard
  • Suite 300
  • Brisbane
  • California
  • 94005-1884
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AIMTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2015
5TADB (Deutsche Boerse AG)YesCommon StockDEEURAug 2015
0HBBLSE (London Stock Exchange)YesCommon StockGBUSDAug 2015

Biography

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Dese ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 03:16
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.